Life Biosciences Appoints Sharon Rosenzweig-Lipson, PhD as Chief Scientific Officer

Dr. Rosenzweig-Lipson brings decades of experience in R&D strategy and clinical development as Life Biosciences advances therapeutics that target the biology of aging

BOSTON, February 13, 2023 – Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced the appointment of Sharon Rosenzweig-Lipson, PhD as Chief Scientific Officer. At Life Biosciences, she will be responsible for leading the company’s scientific research and development efforts built on the epigenetic reprogramming science of Dr. David Sinclair and the chaperone-mediated autophagy discoveries of Dr. Ana Maria Cuervo.

“Dr. Rosenzweig-Lipson brings great scientific and strategic leadership to Life Biosciences,” said Jerry McLaughlin, Chief Executive Officer at Life Biosciences. “Sharon has been serving as a consultant to Life since early 2021 and has helped to create strong processes to accelerate our drug discovery and development. Her impressive background and accomplishments in both preclinical and clinical development will continue to be invaluable to us as we progress our therapies toward the clinic. It is a pleasure to officially welcome her to the team.”

“I am thrilled to be joining Life Biosciences to revolutionize the treatment of a wide-range of age-related disorders,” said Dr. Rosenzweig-Lipson. “I look forward to collaborating with the strong mission-driven team at Life Biosciences and its outstanding scientific collaborators.”

Dr. Rosenzweig-Lipson holds significant expertise in screening strategies, in vivo models, translation, and clinical development strategy with more than three decades of experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry and in biotech. Her career in big pharma includes American Cyanamid, American Home Products, Wyeth, and Pfizer. Most recently, as head of R&D, Dr. Rosenzweig-Lipson led the clinical development of AgeneBio’s lead asset through Phase 2B trials as well as the company’s preclinical development programs. Dr. Rosenzweig-Lipson earned her BA in the biological basis of behavior from the University of Pennsylvania and her PhD in behavioral neuroscience from Harvard University.

About Life Biosciences

Life Biosciences is a private biotechnology company dedicated to discovering and developing novel therapies to improve the lives of people as they age. The company is focusing on two platforms targeting key mechanisms underlying aging biology: epigenetic reprogramming to restore cellular function to a more youthful state and chaperone-mediated autophagy to reverse the age-related decline in the body’s ability to recycle unwanted proteins. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.

Media

media@lifebiosciences.com

Life Biosciences CEO Jerry McLaughlin to Speak at Roadmap to Healthy Longevity International Summit

BOSTON, February 9, 2023  Life Biosciences, a pioneering biotech company developing therapeutics that target the biology of aging, today announced that Jerry McLaughlin, Chief Executive Officer, will speak at the Roadmap to Healthy Longevity: Enabling Healthier, Longer Lives in the GCC conference February 19, 2023, in Riyadh, Saudi Arabia. McLaughlin will participate on a panel entitled “Meet the Healthy Longevity Innovators.”

“Our scientific team at Life Biosciences is at the cutting edge of developing novel therapies based on exciting advances in age-related science,” said McLaughlin. “I’m proud to speak at this important international conference to discuss developments in the bourgeoning healthspan space that are rooted in innovative science as well as to share more about Life’s scientific progress to date and its robust pipeline.”

About the Conference
Jointly organized by the US National Academy of Medicine (NAM), Hevolution Foundation, and the King Abdullah International Medical Research Center (KAIMRC), the event will gather leaders from across the longevity ecosystem to discuss the state of longevity and healthy lifespan in the Gulf Region and an envisioned world with healthy longevity by 2050.

About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to discovering and developing novel therapies to improve the lives of people as they age. The company is focusing on two platforms targeting key mechanisms underlying aging biology: epigenetic reprogramming to restore cellular function to a more youthful state and chaperone-mediated autophagy to reverse the age-related decline in the body’s ability to recycle unwanted proteins. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.

Media
media@lifebiosciences.com

Life Biosciences to Present at Longevity Leaders World Congress 2022

BOSTON, April 14, 2022  Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced that Jerry McLaughlin, Chief Executive Officer, will speak at the fourth annual Longevity Leaders World Congress being held on April 26-27, 2022, in London, UK.

Mr. McLaughlin will deliver a presentation on April 26 at 11:10 BST titled, “Targeting Mechanisms Underlying the Biology of Aging to Treat and Reverse Disease.”

“Life Biosciences is truly at the forefront of developing novel therapies based on exciting advances in age-related science,” says Mr. McLaughlin. “I’m delighted to have the opportunity to share more about our work and progress here at Life Biosciences and discuss ways to work with pioneers in the field to move our industry forward.”

The Longevity Leaders World Congress, hosted by LSX, brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies, and commercialization to target age-related diseases. Those interested in attending the conference may register here.

About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to discovering and developing novel therapies to improve the lives of people as they age. The company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.

Media
media@lifebiosciences.com

Investor Relations
Bill Sullivan
IR@lifebiosciences.com

Life Biosciences, Leading Developer of Therapeutics for Aging-Related Diseases, Completes $82 Million Series C Financing Round

Announces Bill Sullivan as Chief Financial Officer